Etar | List of Frontiers open access articles

Original Research

Published on 08 Aug 2023

Antibodies against angiotensin II receptor type 1 and endothelin A receptor are increased in COVID-19 patients

in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Jelle R. Miedema
Matthijs L. Janssen
Jan von der Thüsen
Henrik Endeman
Anton W. Langerak
Merel E. Hellemons
Els van Nood
Bas W. A. Peeters
Sara J. Baart
Marco W. J. Schreurs

Frontiers in Immunology

doi 10.3389/fimmu.2023.1204433

4,037 views
4 citations

Original Research

Published on 11 Feb 2022

Endothelin-A Receptor Antagonist Alleviates Allergic Airway Inflammation via the Inhibition of ILC2 Function

in Inflammation

Xiaogang Zhang
Ziyang Chen
Shaowen Zuo
Hengbiao Sun
Xinyao Li
Xiao Lu
Zhe Xing
Meiqi Chen
Jingping Liu
Gang Xiao

Frontiers in Immunology

doi 10.3389/fimmu.2022.835953

5,875 views
10 citations

Perspective

Published on 13 May 2021

Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course

in Autoimmune and Autoinflammatory Disorders

Jelle Miedema
Marco Schreurs
Simone van der Sar – van der Brugge
Marthe Paats
Sara Baart
Marleen Bakker
Rogier Hoek
Willem Arnout Dik
Henrik Endeman
Vincent Van Der Velden

Frontiers in Immunology

doi 10.3389/fimmu.2021.684142

6,634 views
34 citations

Original Research

Published on 01 Dec 2021

Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/β-arr1 Axis

in Cell Adhesion and Migration

Danila Del Rio
Ilenia Masi
Valentina Caprara
Francesca Spadaro
Flavia Ottavi
Raffaele Strippoli
Pilar Sandoval
Manuel López-Cabrera
Ricardo Sainz de la Cuesta
Anna Bagnato

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.764375

8,256 views
11 citations

Original Research

Accepted on 02 Feb 2026

Functional Autoantibodies and Coronary Microvascular Obstruction in STEMI: A Translational Link Between Immune Mechanisms and Prognostic Outcomes

in Clinical and Translational Cardiovascular Medicine

Laura Iop
Giovanni Civieri
Giacomo Bernava
Nicola Meynardi
Marta Vadori
Giulia Masiero
Marika Martini
Nicola Morat
Donatella Tansella
Sabino Iliceto

Frontiers in Cardiovascular Medicine

141 views

Original Research

Published on 21 May 2021

Investigation of the Molecular Mechanisms by Which Endothelin-3 Stimulates Preadipocyte Growth

in Experimental Endocrinology

An-Ci Siao
Li-Jane Shih
Yen-Yue Lin
Yi-Wei Tsuei
Yow-Chii Kuo
Hui-Chen Ku
Chih-Ping Chuu
Po-Jen Hsiao
Yung-Hsi Kao

Frontiers in Endocrinology

doi 10.3389/fendo.2021.661828

4,881 views
2 citations

Review

Published on 25 Apr 2022

Novel Therapies for Alport Syndrome

in Nephrology

Efren Chavez
Juanly Rodriguez
Yelena Drexler
Alessia Fornoni

Frontiers in Medicine

doi 10.3389/fmed.2022.848389

36,193 views
46 citations

Review

Published on 19 Apr 2022

Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting

in Cellular Endocrinology

David Speck
Gunnar Kleinau
Michal Szczepek
Dennis Kwiatkowski
Rusan Catar
Aurélie Philippe
Patrick Scheerer

Frontiers in Endocrinology

doi 10.3389/fendo.2022.880002

8,331 views
19 citations

Articles

Antibodies against angiotensin II receptor type 1 and endothelin A receptor are increased in COVID-19 patients

Endothelin-A Receptor Antagonist Alleviates Allergic Airway Inflammation via the Inhibition of ILC2 Function

Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course

Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/β-arr1 Axis

Functional Autoantibodies and Coronary Microvascular Obstruction in STEMI: A Translational Link Between Immune Mechanisms and Prognostic Outcomes

Investigation of the Molecular Mechanisms by Which Endothelin-3 Stimulates Preadipocyte Growth

Novel Therapies for Alport Syndrome

Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting